C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls.
cancer thrombosis
platelet function
podoplanin
soluble CLEC-2
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
15
09
2023
revised:
13
11
2023
accepted:
20
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
The C-type lectin-like receptor 2 (CLEC-2) is expressed on platelets and mediates binding to podoplanin (PDPN) on various cell types. The binding to circulating tumor cells (CTCs) leads to platelet activation and promotes metastatic spread. An increased level of soluble CLEC-2 (sCLEC-2), presumably released from activated platelets, was shown in patients with thromboinflammatory and malignant disease. However, the functional role of sCLEC-2 and the mechanism of sCLEC-2 release are not known. In this study, we focused on the effect of platelet activation on CLEC-2 expression and the sCLEC-2 plasma level in patients with cancer. First, citrated blood from healthy volunteer donors (
Identifiants
pubmed: 38067218
pii: cancers15235514
doi: 10.3390/cancers15235514
pmc: PMC10705117
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Blood. 2016 Jul 7;128(1):24-31
pubmed: 27154188
Innate Immun. 2018 Aug;24(6):335-348
pubmed: 30049243
Lancet Oncol. 2012 May;13(5):518-27
pubmed: 22440112
Blood. 2015 Jun 25;125(26):4069-77
pubmed: 25795918
Res Pract Thromb Haemost. 2019 Oct 17;4(1):23-35
pubmed: 31989082
J Thromb Haemost. 2017 Feb;15(2):219-229
pubmed: 27960039
Lancet. 2012 Apr 28;379(9826):1591-601
pubmed: 22440947
Cancer Biomark. 2021;31(2):99-105
pubmed: 33554888
Cancer Metastasis Rev. 2017 Jun;36(2):225-234
pubmed: 28674748
Neuro Oncol. 2019 Feb 19;21(3):326-336
pubmed: 30418623
BMC Cancer. 2019 Jun 17;19(1):599
pubmed: 31208371
J Thromb Haemost. 2017 Mar;15(3):513-525
pubmed: 28028907
Blood Adv. 2019 Apr 9;3(7):1092-1102
pubmed: 30948364
Sci Rep. 2017 Feb 08;7:42186
pubmed: 28176852
Platelets. 2021 Apr 3;32(3):314-324
pubmed: 32896192
Nat Rev Cancer. 2011 Feb;11(2):123-34
pubmed: 21258396
Am J Cancer Res. 2016 Jan 15;6(2):370-86
pubmed: 27186410
PLoS One. 2013 Aug 21;8(8):e73609
pubmed: 23991201
Lancet. 2012 Apr 28;379(9826):1602-12
pubmed: 22440946
Stroke. 2019 Jan;50(1):45-52
pubmed: 30580704
Cancer Metastasis Rev. 2014 Mar;33(1):231-69
pubmed: 24696047
Platelets. 2015;26(8):711-9
pubmed: 25856065
Arterioscler Thromb Vasc Biol. 2023 Jun;43(6):824-831
pubmed: 37139840
Int J Hematol. 2019 Sep;110(3):285-294
pubmed: 31165998
Int J Colorectal Dis. 2022 Jan;37(1):17-33
pubmed: 34626208
Blood. 2017 Mar 30;129(13):1831-1839
pubmed: 28073783
Thromb Res. 2012 Apr;129 Suppl 1:S30-7
pubmed: 22682130
Blood. 2006 Jan 15;107(2):542-9
pubmed: 16174766
Blood. 2014 Oct 2;124(14):2262-70
pubmed: 25150298
Blood. 2016 Jun 16;127(24):3062-72
pubmed: 26956172
Front Immunol. 2021 Dec 15;12:807600
pubmed: 34987523
J Eur Acad Dermatol Venereol. 2011 Mar;25(3):340-4
pubmed: 20629849
Gastroenterology. 2016 May;150(5):1183-1195.e16
pubmed: 26855187
Thromb Res. 2019 Jun;178:54-58
pubmed: 30978634
Front Immunol. 2021 Jun 09;12:688643
pubmed: 34177942
Front Med. 2020 Feb;14(1):81-90
pubmed: 31280468
Contemp Clin Trials. 2016 Nov;51:56-64
pubmed: 27777129
Platelets. 2021 Nov 17;32(8):1103-1107
pubmed: 33251920
Thromb Res. 2023 Mar;223:36-43
pubmed: 36706720